Lantheus To Present Additional Clinical Data From Phase 3 Pivotal SPLASH Trial In PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress In Barcelona On Sunday, September 15, 2024
Portfolio Pulse from Benzinga Newsdesk
Lantheus Holdings, Inc. will present additional clinical data from its Phase 3 SPLASH trial for PSMA-positive metastatic castration-resistant prostate cancer at the ESMO Congress in Barcelona on September 15, 2024.
August 20, 2024 | 12:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lantheus Holdings is set to present additional clinical data from its Phase 3 SPLASH trial at the ESMO Congress, which could impact its stock price.
The presentation of additional clinical data from a Phase 3 trial is a significant event for Lantheus Holdings. Positive data could lead to increased investor confidence and a potential rise in stock price. The relevance is high as the news directly pertains to Lantheus, and the importance is substantial given the potential impact on stock valuation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100